Stock & Company Details
Kymera Therapeutics Inc $KYMR
Price:
46,691,331
82M
$9.4B
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
-17.68
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Health Technology
KYMR technical indicators
Latest Kymera Therapeutics Inc (KYMR) technical indicators as of 2026-07-01: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
73.11 1.0%
MACD:
8.50 6.0%
SMA 50:
$86.26 0.6%
SMA 200:
$76.09 0.4%
EMA 20:
$96.98 1.9%
Bollinger Bands:
121 / 62.64
Stochastic:
68.31 4.1%
ADX 14:
43.33 6.2%
ATR 14:
6.82 2.6%
CCI 20:
117.04 13.0%
OBV:
36.49M 2.4%
ROC 12:
32.47% 15.1%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
Finance Bot
Ask your questions
Start by typing a question below.
